Scleroderma Induced by Pembrolizumab: A Case Series

Naiara S. Barbosa; David A. Wetter; Carilyn N. Wieland; Niraj K. Shenoy; Svetomir N. Markovic; Uma Thanarajasingam

doi:10.1016/j.mayocp.2017.03.016

Scleroderma Induced by Pembrolizumab: A Case Series

Naiara S. Barbosa, David A. Wetter, Carilyn N. Wieland, Niraj K. Shenoy, Svetomir N. Markovic, Uma Thanarajasingam^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

68 Scopus citations

Abstract

Immune checkpoint inhibitors are approved for select cancer treatment and have shown survival benefit in patients with advanced melanoma. Adverse events, including immune-related adverse events, are common and potentially life-threatening. We describe cases of 2 patients with scleroderma (patient 1 had diffuse scleroderma, and patient 2 had limited scleroderma) that developed while they were receiving pembrolizumab therapy for metastatic melanoma. Prompt recognition and treatment of immune-related adverse events may improve tolerance to immune checkpoint inhibitors and contribute to an understanding of the manifesting autoimmune disease.

Original language	English (US)
Pages (from-to)	1158-1163
Number of pages	6
Journal	Mayo Clinic Proceedings
Volume	92
Issue number	7
DOIs	https://doi.org/10.1016/j.mayocp.2017.03.016
State	Published - Jul 2017
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.mayocp.2017.03.016

Cite this

@article{5a78ef40517c4ab6a290dc51212f3462,

title = "Scleroderma Induced by Pembrolizumab: A Case Series",

abstract = "Immune checkpoint inhibitors are approved for select cancer treatment and have shown survival benefit in patients with advanced melanoma. Adverse events, including immune-related adverse events, are common and potentially life-threatening. We describe cases of 2 patients with scleroderma (patient 1 had diffuse scleroderma, and patient 2 had limited scleroderma) that developed while they were receiving pembrolizumab therapy for metastatic melanoma. Prompt recognition and treatment of immune-related adverse events may improve tolerance to immune checkpoint inhibitors and contribute to an understanding of the manifesting autoimmune disease.",

author = "Barbosa, {Naiara S.} and Wetter, {David A.} and Wieland, {Carilyn N.} and Shenoy, {Niraj K.} and Markovic, {Svetomir N.} and Uma Thanarajasingam",

note = "Publisher Copyright: {\textcopyright} 2017 Mayo Foundation for Medical Education and Research",

year = "2017",

month = jul,

doi = "10.1016/j.mayocp.2017.03.016",

language = "English (US)",

volume = "92",

pages = "1158--1163",

journal = "Mayo Clinic Proceedings",

issn = "0025-6196",

publisher = "Elsevier Science",

number = "7",

}

TY - JOUR

T1 - Scleroderma Induced by Pembrolizumab

T2 - A Case Series

AU - Barbosa, Naiara S.

AU - Wetter, David A.

AU - Wieland, Carilyn N.

AU - Shenoy, Niraj K.

AU - Markovic, Svetomir N.

AU - Thanarajasingam, Uma

PY - 2017/7

Y1 - 2017/7

N2 - Immune checkpoint inhibitors are approved for select cancer treatment and have shown survival benefit in patients with advanced melanoma. Adverse events, including immune-related adverse events, are common and potentially life-threatening. We describe cases of 2 patients with scleroderma (patient 1 had diffuse scleroderma, and patient 2 had limited scleroderma) that developed while they were receiving pembrolizumab therapy for metastatic melanoma. Prompt recognition and treatment of immune-related adverse events may improve tolerance to immune checkpoint inhibitors and contribute to an understanding of the manifesting autoimmune disease.

AB - Immune checkpoint inhibitors are approved for select cancer treatment and have shown survival benefit in patients with advanced melanoma. Adverse events, including immune-related adverse events, are common and potentially life-threatening. We describe cases of 2 patients with scleroderma (patient 1 had diffuse scleroderma, and patient 2 had limited scleroderma) that developed while they were receiving pembrolizumab therapy for metastatic melanoma. Prompt recognition and treatment of immune-related adverse events may improve tolerance to immune checkpoint inhibitors and contribute to an understanding of the manifesting autoimmune disease.

UR - http://www.scopus.com/inward/record.url?scp=85020182824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020182824&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2017.03.016

DO - 10.1016/j.mayocp.2017.03.016

M3 - Article

C2 - 28599746

AN - SCOPUS:85020182824

SN - 0025-6196

VL - 92

SP - 1158

EP - 1163

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

IS - 7

ER -

Scleroderma Induced by Pembrolizumab: A Case Series

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this